The evasion of immune destruction is very interesting. Do metastatic cells have a wider range of mechanisms to evade detection? Is the niche for secondary tumors less accessible to immune detection due to the evasion of recognition?
Novel biomarkers for targeting cancer immunotherapy
Larry H. Bernstein, MD, FCAP, Curator
EFFICACY AND POTENCY TESTING: CELLULAR IMMUNITY
ABL has decades of experience working with human and animal samples to determine the efficacy, activity, and potency of vaccines and therapeutics. Our animal facility is located in close proximity to our laboratories allowing for fresh samples to be delivered in a timely manner for testing in ABL’s laboratories. ABL has a wealth of experience processing many different types of samples (blood, fluids, tissues, washes, etc) and viably freezing cells for shipment or testing at a later date.
In our continuing effort to ensure we are providing our clients with reliable and consistent data, ABL has worked with some of the top academic labs and experts in the country to cross validate our assays and sample collection techniques. This helps give our clients the assurance that the information they receive from…
View original post 821 more words